

This listing of claims will replace all prior versions, and listings, of claims in the application:

In the claims:

1. (previously amended) A method of reducing complement-mediated cytotoxicity in a mammal which comprises

identifying a mammal at risk of developing complement-mediated cytotoxicity; and

administering to said mammal, prior to tissue transplantation, a therapeutically effective amount of interleukin-11, wherein said amount of IL-11 reduces complement-mediated cytotoxicity in said mammal.
2. (original) The method of claim 1, wherein the therapeutically effective amount of interleukin-11 comprises 1 to 100 μ g/kg body weight.
3. (previously amended) A method of ameliorating complement-mediated cytotoxicity in a mammal which comprises

identifying a mammal at risk of developing complement-mediated cytotoxicity; and

administering, at the time of tissue transplantation, a therapeutically effective amount of interleukin-11, wherein said amount of IL-11 ameliorates complement-mediated cytotoxicity in said mammal.

4. (original) The method of claim 4, wherein the therapeutically effective amount of interleukin-11 comprises 1 to 100 µg/kg body weight.

5. (original) The method of claim 4, wherein the interleukin-11 is administered for three days beginning on the day of the tissue transplant.

6. (previously amended) A method of treating complement-mediated cytotoxicity in a mammal which comprises

identifying a mammal with complement-mediated cytotoxicity and
administering to said mammal a therapeutically effective amount of interleukin-11,
wherein said amount of IL-11 reduces complement-mediated cytotoxicity in said mammal.

7. (original) The method of claim 7, wherein the therapeutically effective amount of interleukin-11 comprises 1 to 100µg/kg body weight.

8. (previously amended) The method of claim 7, wherein the interleukin-11 is administered daily until improvement of the complement-mediated cytotoxicity disorder is observed.

9. (previously amended) The method of claim 7, wherein the interleukin-11 is administered daily until remission of the complement-mediated disorder is observed.

10. (previously added) The method of claim 1 wherein said mammal is a human.

11. (previously added) The method of claim 6 wherein said mammal is a human.

Claims 12-20 (cancelled).

21. (newly added). A method of treating complement-mediated cytotoxicity associated with organ or tissue transplantation in a mammal which comprises administering to said mammal a therapeutically effective amount of interleukin-11, wherein said amount of IL-11 reduces complement-mediated cytotoxicity in said mammal.

22. (newly added). The method of claim 21, wherein the therapeutically effective amount of interleukin-11 comprises 1 to 100 μ g/kg body weight.